Mifepristone
- Generic Name
- Mifepristone
- Brand Names
- Korlym, Mifegymiso
- Drug Type
- Small Molecule
- Chemical Formula
- C29H35NO2
- CAS Number
- 84371-65-3
- Unique Ingredient Identifier
- 320T6RNW1F
- Background
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary c...
- Indication
For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
- Associated Conditions
- Hyperglycemia
- Associated Therapies
- Medically induced abortion
Mifepristone for Treatment of Uterine Fibroids
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- Mediterranea Medica S. L.
- Target Recruit Count
- 200
- Registration Number
- NCT00712595
- Locations
- 🇨🇺
Hospital Eusebio Hernández, Havana, Ciudad Habana, Cuba
A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 76
- Registration Number
- NCT00698022
- Locations
- 🇮🇳
Dhirubhai Ambani Life Sciences Centre, Mumbai, India
A Controlled Trial of Mifepristone in Gulf War Veterans With Chronic Multisymptom Illness
- Conditions
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Bronx Veterans Medical Research Foundation, Inc
- Target Recruit Count
- 65
- Registration Number
- NCT00691067
- Locations
- 🇺🇸
James J Peters VA Medical Center, Bronx, New York, United States
Comparing Two Regimens for Medical Abortion: Mifepristone+Misoprostol Versus Misoprostol Alone
- Conditions
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- Gynuity Health Projects
- Target Recruit Count
- 440
- Registration Number
- NCT00680394
- Locations
- 🇹🇳
La Rabta Hospital, Tunis, Tunisia
🇻🇳Hung Vuong Hospital, Ho Chi Minh City, Vietnam
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
- Conditions
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 292
- Registration Number
- NCT00637494
- Locations
- 🇺🇸
Inquest Clinical Group/ Global Research Associates, Hope Mills, North Carolina, United States
🇺🇸Collaborative Neuroscience Network, Inc., Garden Grove, California, United States
🇺🇸Breakthrough Clinical Trials, San Bernardino, California, United States
The Effect of Mifepristone on Uterine Fibroids and Breast Tissue
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 30
- Registration Number
- NCT00579475
- Locations
- 🇸🇪
Dept of Obstetrics and Gynecology, Karolinska University Hospital, Stockholm, Sweden
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT00569582
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
Mifepristone for Patients With Endometrial Cancer and LGESS
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT00505739
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 24
- Registration Number
- NCT00459290
- Locations
- 🇺🇸
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States
🇺🇸Kaiser Permanente Medical Center - Los Angeles, Los Angeles, California, United States
A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain
- Conditions
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2008-09-19
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 57
- Registration Number
- NCT00455442
- Locations
- 🇮🇳
St. John's Medical College, Bangalore, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.